Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
RESEARCH TOOLSreports
Holding CPIX?
Track your performance easily
CPIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.04 - $3.05
Previous Close$2.27
Volume189.89K
Average Volume (3M)1.77M
Market Cap
$31.88M
Enterprise Value$35.58M
Total Cash (Recent Filing)$17.46M
Total Debt (Recent Filing)$21.48M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Mar 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding14,042,304
10 Day Avg. Volume10,831,534
30 Day Avg. Volume1,775,000
Standard Deviation0.16
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.29
Price to Sales (P/S)0.87
Price to Cash Flow (P/CF)16.80
P/FCF Ratio14.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.06
Enterprise Value/Ebitda-24.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cumberland Pharmaceuticals News
PremiumMarket News
3 Penny Stocks to Watch Now, 12/12/24
PremiumCompany Announcements
Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments
Ownership Overview
44.10% Insiders
6.30% Mutual Funds
2.06% Other Institutional Investors
44.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CPIX FAQ
What was Cumberland Pharmaceuticals Inc’s price range in the past 12 months?
Cumberland Pharmaceuticals Inc lowest stock price was $1.04 and its highest was $3.05 in the past 12 months.
What is Cumberland Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Cumberland Pharmaceuticals Inc’s upcoming earnings report date?
Cumberland Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2025 which is in 78 days.
How were Cumberland Pharmaceuticals Inc’s earnings last quarter?
Cumberland Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is Cumberland Pharmaceuticals Inc overvalued?
According to Wall Street analysts Cumberland Pharmaceuticals Inc’s price is currently Overvalued.
Does Cumberland Pharmaceuticals Inc pay dividends?
Cumberland Pharmaceuticals Inc does not currently pay dividends.
What is Cumberland Pharmaceuticals Inc’s EPS estimate?
Cumberland Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cumberland Pharmaceuticals Inc have?
Cumberland Pharmaceuticals Inc has 14,042,304 shares outstanding.
What happened to Cumberland Pharmaceuticals Inc’s price movement after its last earnings report?
Cumberland Pharmaceuticals Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Cumberland Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CPIX
---
Cumberland Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.45%
12-Months-Change
Fundamentals
Return on Equity
-35.76%
Trailing 12-Months
Asset Growth
-12.54%
Trailing 12-Months
Company Description
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Hepatoren, Vaprisol, Boxaban, Vasculan, Ethyol, Portaban, and Totect. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
---
CPIX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Cumberland Pharmaceuticals demonstrated solid performance with Kristalose and Sancuso, coupled with promising international and clinical development efforts. However, Vibativ's challenges due to external factors and a net loss in Q3 indicate areas needing improvement.Read More>---
Technical Analysis
---